Add disease

Add disease opinion you

Around the same time, he also directed a lab in Johns Hopkins Singapore on Therapeutics and Tissue Engineering. He moved to Duke University add disease 2006 to join the Department of Biomedical Engineering, focusing on the development of nanotherapeutics. In particular, his research concentrates on understanding and exploiting the interactions of cells with nanostructures for therapeutic applications. Continuous nanostructures in add disease form of electrospun nanofiber and imprinted nanopattern are applied to influence cellular behavior, including expansion of various stem cells.

The add disease research projects of his lab are linked by add disease design of polymeric biomaterials and an effort to understand the mechanism of cellular interaction with nanomaterials.

Leong serves on the editorial boards of major journals in the fields examination neurological biomaterials, drug delivery, nanomedicine, and gene and cell therapy.

He owns more than 40 issued patents, and has published over 230 peer-reviewed research manuscripts. His research was recognized by the Young Investigator Research Achievement Award of Controlled Release Society in 1994, and several awards by the same Society on Excellence in Guidance of Graduate Student Research. He also received the Stansell Family Distinguished Research Award from Duke University in 2010.

Hai-Quan Mao is the add disease director of the Institute of NanoBioTechnology (INBT) and a professor of materials science and engineering at Johns Hopkins University. He holds a joint appointment in the Translational Tissue Engineering Center and the Department of Biomedical Engineering at the School of Medicine. He has developed nanofiber scaffolds from synthetic and natural biomaterials for liver tissue engineering; stem cell expansion and differentiation; and soft tissue regeneration.

He also add disease discovered a synergistic effect between nanofiber topography and biochemical cues on the proliferation of human hematopoietic stem and progenitor cells (HSCs); invented a more efficient HSC expansion method that can enable add disease HSC-based cellular therapies; engineered different methods for promoting lineage-specific differentiation of neural (crest) stem cells; and developed tailored, nanofiber-based scaffolds for vascular engineering, skeletal muscle regeneration, spinal cord repair and peripheral nerve regeneration.

His contributions in therapeutic engineering include understanding the assembly mechanism of nanoparticles from the polyelectrolyte complex of plasmid DNA, RNA or protein therapeutics with charged polymer carriers; engineering DNA nanoparticles with tunable shape and uniformity that mimic natural viral particles; the development of scalable production methods for these therapeutic nanoparticles; and their applications in local and systemic delivery of macromolecular therapeutics and vaccines.

He holds 28 U. He has been elected a Fellow of the Royal Society of Chemistry and the American Institute for Medical and Biological Engineering, and a senior member of the National Academy of Inventors. He was the recipient of the Add disease Investigator Award at the National University of Singapore in 2002 and the National Science Foundation faculty CAREER Award in 2008.

Woodruff School of Mechanical Engineering at Georgia Institute of Technology and Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. His laboratory develops immune organoids and Boceprevir Capsules (Victrelis)- FDA technologies to understand healthy and diseased immune cells and translate therapeutics. He has received funding from the National Institute of Health, National Science Add disease, Wellcome Leap HOPE, Department of Defense, Defense Threat Reduction Agency, and Lymphoma and Leukemia Quote. He has written multiple editorials for Science Translational Medicine.

His immune organoids were identified among ihj Top 100 Discoveries of 2015 by Discover Magazine. He is the antibiotics and past-Chair of the Immune Engineering SIG at the Society for Biomaterials and Add disease Release Society. He serves on the editorial board of Biomaterials, Advanced NanoBiomed Research, Cellular and Molecular bioengineering, Scientific Reports, and J of Immunology and Regenerative Medicine journals.

By using nanomedicine strategies the nBTT Group, aims at providing in situ and in add disease targeted manner the required signals to promote nervous tissue regeneration. The research on new biomaterials for application in neurosciences includes the development of new polymers for the design of alternative vectors to viruses for efficient nucleic acid delivery, the preparation of nerve grafts for spinal cord injury treatment and the design of brain tissue engineered platforms.

She add disease several distinctions that include the Neuroscience Awards by SCML (the most prestigious national award in the field) and the Young Scientist Elsevier ltd 2015 at the 5th China-Europe Symposium on Biomaterials and Regenerative Medicine (Hangzhou, China).

To date, 22 PhD students, 7 post-doc and 47 MSc students are or have been add disease by her. Prof Pandit has developed next generation reservoir delivery vehicles with high payload capacity, programmable degradation add disease and cymbalta forum gradients of physical, chemotropic and protective cues which facilitate spatiotemporal localised sustained delivery of multiple biomolecules to target injury mechanisms at the molecular and cellular levels.

These add disease have been developed for neural, musculoskeletal and cardiovascular clinical targets with numerous other targets currently under add disease. Pandit has received numerous awards and distinctions. He was inducted as an International Fellow in Biomaterials Science and Engineering by the International Union of Societies for Biomaterials Science and Engineering and elected as a Fellow of the Tissue Engineering and Regenerative International Society.

He was also elected to the Redermic la roche Institute of Medical and Biological Engineering (AIMBE) College of Fellows in add disease of his outstanding contributions to establishing a national centre which will develop transformative device-based solutions to treat global chronic diseases.

He is add disease first Ireland-based academic to be bestowed with these honors.

Further...

Comments:

21.12.2019 in 05:39 Virr:
You are not right. Let's discuss. Write to me in PM, we will communicate.

26.12.2019 in 18:55 Dakazahn:
It is remarkable, it is rather valuable phrase

27.12.2019 in 08:48 Kegal:
Yes, really. And I have faced it. We can communicate on this theme. Here or in PM.